Nivolumab 10 MG/ML Intravenous Solution

DRUG3 trials

Sponsors

Gruppo Oncologico Italiano di Ricerca Clinica, University Hospital, Essen, Jules Bordet Institute

Conditions

NSCLC Stage IINSCLC, Stage INSCLC, Stage IIIARectal Cancer Stage IIRectal Cancer Stage IIISquamous Non-small Cell Lung Cancer

Phase 2

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

RecruitingNCT04205552

University Hospital, EssenNSCLC, Stage I, NSCLC Stage II, NSCLC, Stage IIIA

Start: 2020-03-04End: 2025-06-30Target: 90Updated: 2024-05-09

Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Active, not recruitingNCT04503694

Jules Bordet InstituteRectal Cancer Stage II, Rectal Cancer Stage III

Start: 2021-03-25End: 2032-12-01Target: 72Updated: 2026-03-27

Phase 3

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

Gruppo Oncologico Italiano di Ricerca ClinicaSquamous Non-small Cell Lung Cancer

Start: 2017-09-25End: 2023-01-31Updated: 2022-10-03

Related Papers

Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).

2025-12-05

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.

2024-12-15

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Nature Medicine2024-04-3069 citations

Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.

Journal of Clinical Oncology2023-06-0111 citations

REGINA: A phase II trial of neoadjuvant regorafenib (Rego) in combination with nivolumab (Nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC).

Journal of Clinical Oncology2022-01-193 citations

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial

Annals of Oncology2019-04-01